ProMIS Neurosciences is trading 5.1% down at $14.16 as investors lock in gains following a sharp multi-day rally and a broader decline in the biotech sector.
- The move comes without fresh company-specific news, appearing to be a technical correction after significant gains earlier this week.
- Broader market sentiment for biotech is cooling, with the XBI biotech ETF dropping over 3% today.
- Risk appetite is waning across the sector as investors pull back following recent strength.